Optimal Management of Favorable Risk Clear Cell RCC Combination Therapy

André P. Fay, MD, PhD Professor, PUCRS School of Medicine Chief, Medical Oncology Department – Oncoclínicas/HSL-PUCRS Visiting Scientist at Dana-Farber Cancer Institute/ Harvard Medical School discusses
Optimal Management of Favorable Risk Clear Cell RCC Combination Therapy at the 18th International Kidney Cancer Symposium 2019, Miami, FL.